WebApr 10, 2024 · Dr Joel Gelfand from Penn Medicine in Philadelphia, Pennsylvania, discusses a study examining whether the Janus kinase (JAK) inhibitor abrocitinib provided safe and effective disease control for... WebApr 10, 2024 · April 10, 2024 Dr Joel Gelfand from Penn Medicine in Philadelphia, Pennsylvania, reports on the latest research on psoriasis and related disorders presented at the 2024 American Academy of...
Joel M Gelfand Faculty About Us Perelman School of Medicine ...
WebDr. Joel Gelfand Discusses the Mental Impact of Psoriasis; Management and Treatment of Psoriasis with Phototherapy; ... Gelfand Clinical Research Lab. 215-662-SKIN Email Us Directions Follow Us LinkedIn Twitter; Links of Interest. Dr. Gelfand's Publications; Penn Dermatology; Center for Clinical Epidemiology and Biostatistics ... WebDr. Gelfand Clinical Research Lab Faculty Website Dermatology Clinical Effectiveness Research Network (DCERN) Education: B.S. (Biology, Community Health) Tufts University, 1993. ... Cohort study using General Practice Research Database. European Heart Journal 31: 1000-06, 2010. cook\\u0027s newton ms
Gelfand Lab Gelfand Clinical Research Lab Perelman …
WebUrko del Castillo, PhD. Associated with Gelfand’s lab from 2011 to 2024 as Post doctoral research fellow. Currently, he is working as Research Associate at Weill Cornell Medicine, Division of Hematology and Medical Oncology, New York. WebThe Gelfand Clinical Research Lab designs and conducts clinic-based and population-based observational studies and interventional and translational clinical trials in common and rare skin diseases. Gelfand and his team focus on pharmacoepidemiology, patient centered outcomes and effectiveness research, psychometrics and … WebResearch Gelfand Clinical Research Lab Perelman School of Medicine at the University of Pennsylvania Research Research Current Studies LITE Study Light Treatment Effectiveness Study PI: Joel M. Gelfand, MD, MSCE CP3 Study Cardiovascular Disease Prevention for Psoriasis and Psoriatic Arthritis PI: Joel M. Gelfand, MD, MSCE family investments sovereign 3 series 4 price